AR066170A1 - Anti integrina alfa 5 beta 1 - Google Patents
Anti integrina alfa 5 beta 1Info
- Publication number
- AR066170A1 AR066170A1 ARP080104170A ARP080104170A AR066170A1 AR 066170 A1 AR066170 A1 AR 066170A1 AR P080104170 A ARP080104170 A AR P080104170A AR P080104170 A ARP080104170 A AR P080104170A AR 066170 A1 AR066170 A1 AR 066170A1
- Authority
- AR
- Argentina
- Prior art keywords
- sequence
- amino acid
- acid sequence
- identifier
- sequence identifier
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 abstract 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 abstract 1
- 230000018103 negative regulation of vascular permeability Effects 0.000 abstract 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente se refiere al uso de antagonistas del factor de crecimiento celular endotelial vascular (VEGF) y un anticuerpo alfa5beta1 para el tratamiento del cáncer y la inhibicion de la angiogénesis y/o la permeabilidad vascular, incluso, en la angiogénesis anormal en enfermedades. La presente también se relaciona con las composiciones y kits que comprenden los anticuerpos los anti-alfa5beta1 y los métodos para desarrollarlos o utilizarlos. Reivindicacion 1: Un anticuerpo anti-alfa5beta1 que comprende una secuencia de dominio variable de cadena ligera que comprende (1) un LHVR1 que comprende una secuencia de aminoácidos KASQ-N/S-VGSDVA (identificador de secuencia n°: 10), (2) un LHVR2 que comprende la secuencia de aminoácidos STSYRYS (identificador de secuencia n°: 11) y (3) un LHVR3 que comprende la secuencia de aminoácidos QQY-N/S-SYPFT (identificador de secuencia n°: 12) y una secuencia de dominio variable de cadena pesada que comprende (1) un HHVR1 que comprende la secuencia de aminoácidos GYTF-T/S-DYYLY (identificador de secuencia n°:13), (2) un HHVR2 que comprende la secuencia de aminoácidos GISPS-N/S-GGTTF-N/A-D-N/A-FE-N/G (identificador de secuencia n°:14) y (3) un HHVR3 que comprende la secuencia de aminoácidos DAYGDWYFDV (identificador de secuencia n°:15).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97547107P | 2007-09-26 | 2007-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066170A1 true AR066170A1 (es) | 2009-07-29 |
Family
ID=40329277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104170A AR066170A1 (es) | 2007-09-26 | 2008-09-25 | Anti integrina alfa 5 beta 1 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7973138B2 (es) |
| EP (1) | EP2200700B1 (es) |
| JP (1) | JP2011501656A (es) |
| KR (1) | KR20100065162A (es) |
| CN (1) | CN101888878B (es) |
| AR (1) | AR066170A1 (es) |
| AU (1) | AU2008304452B2 (es) |
| BR (1) | BRPI0816049A2 (es) |
| CA (1) | CA2698609A1 (es) |
| CL (1) | CL2008002856A1 (es) |
| CO (1) | CO6260094A2 (es) |
| DK (1) | DK2200700T3 (es) |
| HR (1) | HRP20160308T1 (es) |
| HU (1) | HUE027911T2 (es) |
| MX (1) | MX2010003325A (es) |
| MY (1) | MY151191A (es) |
| NZ (1) | NZ584838A (es) |
| PE (1) | PE20091029A1 (es) |
| RU (1) | RU2490277C2 (es) |
| SI (1) | SI2200700T1 (es) |
| TW (1) | TWI547503B (es) |
| WO (1) | WO2009042746A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20160308T1 (hr) | 2007-09-26 | 2016-04-22 | Genentech, Inc. | Nova protutijela |
| JP6051048B2 (ja) | 2009-03-25 | 2016-12-21 | ジェネンテック， インコーポレイテッド | 新規な抗α５β１抗体及びその使用 |
| CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| US8404811B2 (en) * | 2009-05-08 | 2013-03-26 | Genentech, Inc. | Humanized anti-EGFL7 antibodies and methods using same |
| US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
| US20130058926A1 (en) * | 2011-08-30 | 2013-03-07 | Shiseido Company, Ltd. | Method for alleviating and/or preventing skin reddening |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| WO2013152011A1 (en) * | 2012-04-02 | 2013-10-10 | Ab Biosciences, Inc. | Novel human control antibodies and uses therefor |
| KR102023401B1 (ko) | 2012-05-10 | 2019-11-04 | 바이오아트라, 엘엘씨 | 다중-특이적 모노클로날 항체 |
| US9429577B2 (en) | 2012-09-27 | 2016-08-30 | Biocare Medical, Llc | Anti-uroplakin II antibodies systems and methods |
| US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| RU2681994C2 (ru) * | 2012-12-26 | 2019-03-14 | Онкосинерджи, Инк. | КОМПОЗИЦИИ АНТИТЕЛА К ИНТЕГРИНУ β1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US9988442B2 (en) | 2013-01-23 | 2018-06-05 | Syddansk Universitet | MFAP4 binding antibodies blocking the interaction between MFAP4 and integrin receptors |
| EP2953974B1 (en) * | 2013-02-05 | 2017-12-20 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and bcma |
| DK2962113T3 (da) | 2013-02-28 | 2019-07-01 | Biocare Medical Llc | Systemer og fremgangsmåder med anti-p40-antistoffer |
| DK3052522T3 (da) | 2013-10-03 | 2020-02-24 | Biocare Medical Llc | Anti-sox 10 antistofsystemer og -fremgangsmåder |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| CN108693004B (zh) * | 2018-05-24 | 2020-08-04 | 中国农业科学院农业质量标准与检测技术研究所 | 一种检测菜籽粕中是否掺杂抗生素滤渣的方法 |
| KR20210009421A (ko) | 2018-06-14 | 2021-01-26 | 바이오아트라, 엘엘씨 | 다중 특이적 항체 구조체 |
| JP7596298B2 (ja) * | 2019-04-01 | 2024-12-09 | クリア・アイピー・ホールディングス・リミテッド・ライアビリティ・カンパニー | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN114688461B (zh) * | 2020-12-31 | 2025-02-28 | 青岛海尔施特劳斯水设备有限公司 | 一种漏水检测方法及系统 |
| CN113133431A (zh) * | 2021-02-25 | 2021-07-20 | 中南大学 | 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用 |
| CN114073996B (zh) * | 2021-11-24 | 2023-04-14 | 中山大学 | 一种嵌套式微井阵列芯片及其制备方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5540933A (en) | 1985-05-31 | 1996-07-30 | La Jolla Cancer Research Foundation | Isolation and use of fibronectin receptor |
| EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
| US20020146410A1 (en) | 1992-05-22 | 2002-10-10 | Helmut Eckert | Monoclonal antibodies and their use |
| US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| PT719859E (pt) | 1994-12-20 | 2003-11-28 | Merck Patent Gmbh | Anticorpo monoclonal anti-alfa v-integrina |
| DE69930723T2 (de) | 1998-01-23 | 2006-11-16 | Merck Patent Gmbh | Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6-integrin und fibronectin in vitro zu hemmen |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| EP2327451B1 (en) | 1998-05-08 | 2013-10-23 | The Regents of the University of California | Method for detecting and inhibiting angiogenesis |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB9909392D0 (en) | 1999-04-24 | 1999-06-23 | Imp Cancer Res Tech | Treatment, imaging and diagnosis of disease |
| US20030152926A1 (en) | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| US20020015970A1 (en) | 1999-08-11 | 2002-02-07 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
| MXPA02001439A (es) | 1999-08-11 | 2002-08-30 | Eos Biotechnology Inc | Nuevos metodos para el diagnostico de angiogenesis, composiciones y metodos de exhibicion de moduladores de la angiogenesis. |
| US20020019330A1 (en) | 1999-08-11 | 2002-02-14 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
| US20040009494A1 (en) | 1999-08-11 | 2004-01-15 | Richard Murray | Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators |
| US20040259152A1 (en) | 2000-02-22 | 2004-12-23 | Richard Murray | Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases |
| WO2002079492A2 (en) | 2001-02-14 | 2002-10-10 | Protein Design Labs, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| JP2005527180A (ja) | 2001-04-18 | 2005-09-15 | プロテイン デザイン ラブス， インコーポレイテッド | 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法 |
| WO2002098358A2 (en) | 2001-06-04 | 2002-12-12 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
| AU2002347428A1 (en) | 2001-06-18 | 2003-01-02 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20070042360A1 (en) | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| EP1434881A4 (en) | 2001-09-17 | 2005-10-26 | Protein Design Labs Inc | METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS |
| US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| AU2003256307A1 (en) | 2002-06-25 | 2004-01-06 | The Regents Of The University Of California | Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
| EP1539247A4 (en) | 2002-07-16 | 2007-08-29 | Univ New Jersey Med | ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATH |
| US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| RU2346701C2 (ru) * | 2002-11-26 | 2009-02-20 | ПиДиЭл БАЙОФАРМА ИНК. | ХИМЕРНЫЕ И ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ ИНТЕГРИНА α5β1, КОТОРЫЕ МОДУЛИРУЮТ АНГИОГЕНЕЗ |
| US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| WO2004048938A2 (en) | 2002-11-26 | 2004-06-10 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| EP1625165A2 (en) | 2003-04-03 | 2006-02-15 | Protein Design Labs, Inc. | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
| KR20070009637A (ko) * | 2004-03-24 | 2007-01-18 | 피디엘 바이오파르마 인코포레이티드 | 암 세포 증식을 억제하는 항α5β1 항체의 용도 |
| US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| ES2539126T3 (es) | 2004-12-09 | 2015-06-26 | Janssen Biotech, Inc. | Inmunoconjugados anti integrina, métodos para su producción y su uso |
| US20090111828A1 (en) | 2005-11-23 | 2009-04-30 | Astrazeneca Ab | L-alanine derivatives |
| US20090137601A1 (en) | 2005-11-23 | 2009-05-28 | Astrazeneca Ab | L-Phenylalanine Derivatives |
| EP1984330A1 (en) | 2006-02-09 | 2008-10-29 | AstraZeneca AB | Chemical compounds |
| US20090220504A1 (en) * | 2006-03-21 | 2009-09-03 | Anan Chuntharapai | Combinatorial therapy |
| CA2652886A1 (en) | 2006-05-24 | 2007-11-29 | Bayer Schering Pharma Aktiengesellschaft | High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity |
| HRP20160308T1 (hr) | 2007-09-26 | 2016-04-22 | Genentech, Inc. | Nova protutijela |
| EP2641612A1 (en) | 2008-02-05 | 2013-09-25 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
-
2008
- 2008-09-25 HR HRP20160308TT patent/HRP20160308T1/hr unknown
- 2008-09-25 DK DK08834260.5T patent/DK2200700T3/en active
- 2008-09-25 AU AU2008304452A patent/AU2008304452B2/en not_active Ceased
- 2008-09-25 BR BRPI0816049A patent/BRPI0816049A2/pt not_active IP Right Cessation
- 2008-09-25 TW TW097136935A patent/TWI547503B/zh not_active IP Right Cessation
- 2008-09-25 PE PE2008001669A patent/PE20091029A1/es not_active Application Discontinuation
- 2008-09-25 MY MYPI20101284 patent/MY151191A/en unknown
- 2008-09-25 SI SI200831589T patent/SI2200700T1/sl unknown
- 2008-09-25 WO PCT/US2008/077622 patent/WO2009042746A1/en not_active Ceased
- 2008-09-25 HU HUE08834260A patent/HUE027911T2/en unknown
- 2008-09-25 CL CL2008002856A patent/CL2008002856A1/es unknown
- 2008-09-25 MX MX2010003325A patent/MX2010003325A/es active IP Right Grant
- 2008-09-25 KR KR1020107006513A patent/KR20100065162A/ko not_active Abandoned
- 2008-09-25 JP JP2010527128A patent/JP2011501656A/ja active Pending
- 2008-09-25 EP EP08834260.5A patent/EP2200700B1/en active Active
- 2008-09-25 RU RU2010116184/10A patent/RU2490277C2/ru not_active IP Right Cessation
- 2008-09-25 CN CN200880117702.0A patent/CN101888878B/zh not_active Expired - Fee Related
- 2008-09-25 NZ NZ584838A patent/NZ584838A/xx not_active IP Right Cessation
- 2008-09-25 CA CA2698609A patent/CA2698609A1/en not_active Abandoned
- 2008-09-25 US US12/237,640 patent/US7973138B2/en not_active Expired - Fee Related
- 2008-09-25 AR ARP080104170A patent/AR066170A1/es unknown
-
2010
- 2010-03-19 CO CO10033130A patent/CO6260094A2/es active IP Right Grant
-
2011
- 2011-05-20 US US13/112,833 patent/US9284376B2/en not_active Expired - Fee Related
- 2011-05-20 US US13/112,839 patent/US8840887B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2490277C2 (ru) | 2013-08-20 |
| AU2008304452B2 (en) | 2014-01-16 |
| TWI547503B (zh) | 2016-09-01 |
| JP2011501656A (ja) | 2011-01-13 |
| WO2009042746A1 (en) | 2009-04-02 |
| US20120148572A1 (en) | 2012-06-14 |
| US20120156129A1 (en) | 2012-06-21 |
| HRP20160308T1 (hr) | 2016-04-22 |
| CN101888878B (zh) | 2014-05-21 |
| US7973138B2 (en) | 2011-07-05 |
| MX2010003325A (es) | 2010-04-09 |
| CO6260094A2 (es) | 2011-03-22 |
| TW200924794A (en) | 2009-06-16 |
| SI2200700T1 (sl) | 2016-04-29 |
| CL2008002856A1 (es) | 2009-01-16 |
| EP2200700B1 (en) | 2016-01-13 |
| PE20091029A1 (es) | 2009-08-19 |
| EP2200700A1 (en) | 2010-06-30 |
| NZ584838A (en) | 2012-08-31 |
| AU2008304452A1 (en) | 2009-04-02 |
| US8840887B2 (en) | 2014-09-23 |
| CN101888878A (zh) | 2010-11-17 |
| HUE027911T2 (en) | 2016-11-28 |
| RU2010116184A (ru) | 2011-11-10 |
| US9284376B2 (en) | 2016-03-15 |
| CA2698609A1 (en) | 2009-04-02 |
| KR20100065162A (ko) | 2010-06-15 |
| MY151191A (en) | 2014-04-30 |
| DK2200700T3 (en) | 2016-04-11 |
| US20090098112A1 (en) | 2009-04-16 |
| BRPI0816049A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066170A1 (es) | Anti integrina alfa 5 beta 1 | |
| ECSP088835A (es) | Terapia combinatoria que involucra antagonistas de alfa5beta1 | |
| CL2012000631A1 (es) | Anticuerpo capaz de unirse específicamente a un amiloide beta, que comprende los 3 cdrs de cadena liviana (sec nº21/22/23) y los 3 cdrs de cadena pesada (sec nº24/25/26); polinucleótido y línea celular que lo codifican; composición que lo comprende; método de producción y diagnostico; kit; y su uso terapéutico. | |
| CY1122060T1 (el) | Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων | |
| AR065496A1 (es) | Anticuerpos anti- il-23 r | |
| AR068997A1 (es) | Anticuerpos contra el vegf completamente humano y sus metodos de uso | |
| CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
| HN2008001104A (es) | Compuestos para anticuerpos de dickpf-1 y70-4 | |
| AR079336A1 (es) | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| PE20241349A1 (es) | Anticuerpos de union a cd3 | |
| AR060241A1 (es) | Composiciones y metodos de uso para anticuerpos de c-met | |
| CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| CL2012000229A1 (es) | Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular. | |
| AR070346A1 (es) | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos | |
| EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
| CL2009001476A1 (es) | Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular. | |
| NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| AR077756A1 (es) | Anticuerpos especificos para bacterias gram-positivas | |
| AR057237A1 (es) | Metodos y composiciones para actuar sobre la poliubiquitina | |
| ES2674567T3 (es) | Proteínas de fusión biespecíficas | |
| CO6331346A2 (es) | Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo | |
| AR076655A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| EA201590459A1 (ru) | Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |